Multicentre, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines

Dermatologic Surgery

Volumn 39, Issue 7, 2013, Pages 1118-1119

  Fulford Smith, Antony ^a   Gallagher, Conor J ^b   Brin, Mitchell F ^b  

^a ALLERGAN PLC   (United States)

^b ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PLACEBO; PROTEIN;

CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; GLABELLAR FROWN LINE; HUMAN; LETTER; MULTICENTER STUDY; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; MALE; NEUROMUSCULAR AGENTS; SKIN AGING;

EID: 84879889703     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/dsu.12101     Document Type: Letter

References (4)

1. Carruthers A, Carruthers J, Coleman W, Donofrio L, et al. Multicentre, randomized, Phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatol Surg 2013; 39 (4): 551-8.
2. Carruthers A, Carruthers J, Said S,. Dose ranging study of botulinum toxin type A in the treatment of glabellar rhytides in females. Dermatol Surg 2005; 31: 414-22.
3. Carruthers A, Carruhers J, Lowe NJ, Menter A, et al. One year randomised, multicenter, two period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. J Clin Res 2004; 7: 1-20.
4. Sattler G, Callander M, Grablowitz D, Walker T, et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg 2010; 36: 2146-54.